HAYWARD, Calif.--Lynx Therapeutics announced that it will collaborate with Oxagen of Oxford, UK, to discover and validate disease-associated single-nucleotide polymorphisms (SNPs). The program will initially focus on inflammatory bowel disease, but may be extended to other common disorders. No financial terms were disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.